Synapse - Heather Landau

Search Within

Heather Jolie Landau

Results (162)

Efficacy and risk factors analysis of upfront autologous stem cell mobilization using plerixafor and granulocyte-colony stimulating factor (GCSF) in patients with multiple myeloma

Meeting Abstract

Ogunniyi, A.; Rodriguez, M.; Devlin, S. M.; Adel, N. G.; Landau, H.; Chung, D. J.; Lendvai, N.; Lesokhin, A. M.; Landgren, O.; Giralt, S. A.; more...
Blood (2014)

Fulltext@MSK | Save

Increased bone marrow plasma cells at diagnosis predicts overall mortality in AL amyloidosis patients undergoing risk-adapted stem cell transplant

Meeting Abstract

Landry, C. A.; Smith, M.; Chou, J. F.; Devlin, S. M.; Hassoun, H.; Bello, C.; Landgren, O.; Giralt, S.; Comenzo, R. L.; Landau, H.
Blood (2014)

Fulltext@MSK | Save

Greater total dose and duration of treatment with bortezomib are associated with higher incidence of chalazion and other ocular side effects

Meeting Abstract

Ganesh, K.; Batlevi, C.; Zhang, Z. G.; Hassoun, H.; Lendvai, N.; Landau, H.; Moskowitz, C. H.; Caron, P.; Motzer, R.; Giralt, S. A.; more...
Blood (2014)

Fulltext@MSK | Save

Analysis of VDT-PACE utilization in multiple myeloma patients treated at MSKCC for relapsed disease or cytoreduction and stem cell mobilization after initial induction therapy

Meeting Abstract

Beyer, K.; Rosner, S.; Woo, K. M.; Devlin, S. M.; Landau, H.; Hassoun, H.; Lendvai, N.; Chung, D. J.; Adel, N. G.; Puto, M.; more...
Blood (2014)

Fulltext@MSK | Save

Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for autologous stem cell mobilization in multiple myeloma patients: An update on cost analysis study at Memorial Sloan Kettering Cancer Center

Meeting Abstract

Afifi, S.; Adel, N. G.; Duck, E.; Devlin, S. M.; Landau, H.; Lendvai, N.; Lesokhin, A. M.; Chung, D. J.; Landgren, O.; Giralt, S. A.; more...
Blood (2014)

Fulltext@MSK | Save

A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma

Journal Article

Lendvai, N.; Hilden, P.; Devlin, S.; Landau, H.; Hassoun, H.; Lesokhin, A. M.; Tsakos, I.; Redling, K.; Koehne, G.; Chung, D. J.; more...
Blood (2014)

Fulltext@MSK | Save

T-cell depleted allogeneic HSCT for patients with relapsed, high-risk multiple myeloma permits long-lasting remissions in the absence of graft-versus-host disease and provides a platform for adoptive immunotherapeutic approaches

Meeting Abstract

Koehne, G.; Devlin, S.; Landau, H.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Chung, D. J.; Bravo, C.; Giralt, S. A.
Biology of Blood and Marrow Transplantation (2014)

Fulltext@MSK | Save

Second autologous stem cell transplant- an effective eherapy for relapsed multiple myeloma

Meeting Abstract

Abbi, K.; Devlin, S.; Giralt, S. A.; Landau, H.
Biology of Blood and Marrow Transplantation (2014)

Fulltext@MSK | Save

Multiple copies of MLL is the most commonly detected cytogenetic abnormality in newly diagnosed multiple myeloma and may modify disease risk

Meeting Abstract

Landry, C.; Londono, D.; Devlin, S. M.; Lesokhin, A.; Lendvai, N.; Hassoun, H.; Chung, D. J.; Koehne, G.; Jhanwar, S. C.; Giralt, S. A.; more...
Blood (2013)

Fulltext@MSK | Save

Pilot study to evaluate the prevalence of actionable oncogenic mutations in patients with relapsed refractory multiple myeloma

Meeting Abstract

Lesokhin, A.; Gonen, M.; Redling, K.; Lendvai, N.; Hassoun, H.; Landau, H.; Chung, D. J.; Koehne, G.; Patel, M.; Brennan, K. W.; more...
Blood (2013)

Fulltext@MSK | Save